In a significant advancement for hematological oncology, researchers at the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) have unveiled a novel therapeutic regimen that is reshaping the treatment landscape for Acute Myeloid Leukemia (AML). The combination therapy, dubbed "QUIZOM," has demonstrated a remarkable ability to induce remission in patients with FLT3-mutated AML, a notoriously aggressive form of blood cancer that has long frustrated clinicians due to its high propensity for relapse and resistance to standard chemotherapy.
By integrating the precision of targeted inhibitors with the modulation of cellular protein synthesis and immune activation, this dual-drug approach has achieved an 83% composite complete remission (CRc) rate. Beyond the immediate clinical response, the therapy serves a critical strategic purpose: it provides a vital bridge for patients to undergo hematopoietic stem cell transplantation (HSCT), the only curative path for many high-risk leukemia patients.
The Challenge of FLT3-Mutated AML
Acute Myeloid Leukemia is characterized by the rapid, uncontrolled proliferation of abnormal white blood cells that crowd out healthy bone marrow. Among the various genetic subsets of AML, those harboring FLT3 gene mutations are particularly concerning. Occurring in roughly 30% of all AML cases, these mutations drive aggressive disease progression and are statistically linked to poorer patient outcomes.
Historically, patients with these mutations have faced a grim reality. While FLT3 inhibitors—drugs specifically designed to target the mutated protein—can offer temporary relief, they frequently fail to prevent the emergence of treatment-resistant cancer clones. Consequently, many patients find themselves in a state of clinical limbo: too frail or biologically compromised to withstand conventional chemotherapy, yet facing an inevitable relapse if a definitive treatment like an HSCT is not performed. The QUIZOM regimen, led by Professor Anskar Leung Yu-hung of HKUMed, was specifically engineered to overcome this bottleneck.
Chronology of the Research and Clinical Validation
The journey to the discovery of QUIZOM was a multi-year endeavor that bridged the gap between fundamental laboratory discovery and clinical application.
Phase 1: Conceptualization and Laboratory Foundations
The research team began by analyzing the limitations of monotherapy. They observed that while FLT3 inhibitors silenced the immediate signal for cell division, leukemic stem cells possessed intrinsic mechanisms to survive the blockade. This led to the hypothesis that a synergistic partner was required to destabilize the cancer cell’s internal machinery.
Phase 2: The Clinical Trial (2017–2020)
Between November 2017 and September 2020, the HKUMed team conducted a formal Phase 2 clinical trial. The cohort consisted of 40 patients, ranging in age from 23 to 81. Crucially, these were not newly diagnosed "ideal" candidates; they were individuals whose leukemia had proven refractory—or resistant—to standard chemotherapy. The administration of Quizartinib (an FLT3 inhibitor) in combination with Omacetaxine Mepesuccinate (a protein synthesis inhibitor) formed the core of the QUIZOM protocol.
Phase 3: Mechanistic Multi-Omics Analysis
Following the trial’s conclusion, the researchers employed high-resolution multi-omics—a sophisticated technique that maps the entire genetic and molecular state of individual cells—to understand why the therapy succeeded where others failed. This analysis provided the "smoking gun" evidence that QUIZOM does more than just kill cancer; it re-engineers the patient’s internal environment to favor recovery.
Supporting Data: Clinical Efficacy and Patient Outcomes
The statistical outcomes from the Phase 2 trial provide a compelling case for the adoption of QUIZOM as a standard consideration for high-risk cohorts.
- Composite Complete Remission (CRc) Rate: Approximately 83% of participants achieved a level of remission that allowed for clinical stability.
- Survival Metrics: The median leukemia-free survival (LFS) reached 10 months, with a median overall survival of 12.9 months.
- Transplant Success: Thirteen patients, who were previously deemed unsuitable or too high-risk for transplant, were successfully bridged to allogeneic HSCT following the QUIZOM intervention.
Perhaps most significantly, the data shows that the combination is not merely additive but synergistic. The multi-omics profiling revealed that the treatment effectively disrupts the protein metabolism of leukemic cells. By inhibiting protein folding—a process upon which cancer cells are hyper-dependent—the therapy effectively triggers "cellular stress," making the cells vulnerable to the patient’s own T-cell immune system. In essence, the therapy turns the patient’s body into an active participant in the destruction of the cancer.
Unveiling the Mechanism: Overcoming Resistance
A major focus of the study was identifying why some patients eventually relapse. Through single-cell gene expression profiling, the team identified a sub-population of stem-cell-like leukemic cells that act as a "reservoir" for future relapse.
These resilient cells utilize a specific pathway—PLD1-mediated phospholipid metabolism—to facilitate protein folding even under the pressure of drugs. This allows them to survive, hide, and eventually re-emerge as a full-blown recurrence. The discovery that the addition of a PLD1 inhibitor could neutralize this survival mechanism is perhaps the most significant scientific takeaway of the study. By blocking this specific metabolic escape route, the researchers have effectively "closed the door" on the primary method these cancer cells use to resist treatment.
Official Responses and Perspectives
Professor Anskar Leung Yu-hung, who spearheaded the study, has been clear about the implications of these findings. "The QUIZOM combination therapy provides an effective and feasible treatment option for patients with FLT3-mutated AML who are unfit for conventional chemotherapy," Professor Leung stated.
He emphasized that the goal is not to replace the transplant, but to make it possible. "By improving the remission rate, patients are better positioned to proceed to HSCT as consolidation therapy. With post-transplant maintenance and monitoring, the majority of patients can achieve sustained remission."
The research community has received these findings with considerable optimism. By moving beyond the "one-drug-one-target" philosophy and embracing a systems-biology approach, the HKUMed team has demonstrated how metabolic inhibitors can be used to "sensitize" cancer cells to immunotherapy, a strategy that is likely to be adapted for other forms of aggressive blood cancers in the coming years.
Implications for Future Oncology
The publication of these findings in Nature Communications marks a turning point in the management of high-risk AML. The implications are twofold:
1. Expanding the Eligibility for Life-Saving Transplants
The most immediate impact is the expansion of the patient pool eligible for HSCT. Previously, patients with refractory FLT3-mutated AML were often excluded from transplant lists because they could not achieve a low-disease-burden state required for a successful procedure. QUIZOM acts as a highly effective "bridge," cleaning the marrow and allowing physicians to perform transplants on patients who were previously considered terminal.
2. The Rise of Combination Metabolism-Targeted Therapy
The identification of the PLD1 pathway as a driver of drug resistance has opened a new frontier in drug development. The research team has already filed a patent for the application of PLD1 inhibitors in leukemia. This suggests a future where "metabolic precision" becomes a staple of oncology, where clinicians analyze a patient’s metabolic profile to determine which combination of inhibitors will be most effective at preventing the specific resistance mechanisms of their unique cancer.
Conclusion: A New Standard of Care?
As the medical community digests the results of the HKUMed study, the focus now shifts toward larger, multi-center trials to validate these findings on a global scale. While the Phase 2 results are robust, the ultimate goal is to integrate QUIZOM into international treatment guidelines, ensuring that patients worldwide have access to this life-extending strategy.
By combining the precision of molecular inhibitors with the power of the patient’s own immune system, the QUIZOM regimen represents the best of modern translational medicine: a marriage of deep mechanistic inquiry and clinical pragmatism. For the thousands of patients diagnosed with FLT3-mutated AML each year, this breakthrough offers not just a temporary reprieve, but a genuine path toward long-term survival. The battle against high-risk blood cancer is far from over, but with the advent of strategies like QUIZOM, the odds are increasingly shifting in the favor of the patient.
About the Author
